- Investing.com
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Metrics to compare | MARI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMARIPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.0x | −5.9x | −0.6x | |
PEG Ratio | - | −0.02 | 0.00 | |
Price/Book | −1.2x | 0.5x | 2.6x | |
Price / LTM Sales | 2.1x | 1.9x | 3.2x | |
Upside (Analyst Target) | - | 72.4% | 48.6% | |
Fair Value Upside | Unlock | 9.3% | 7.0% | Unlock |